A framework for understanding cancer comparative effectiveness research data needs
- PMID: 23017633
- PMCID: PMC3461183
- DOI: 10.1016/j.jclinepi.2012.06.005
A framework for understanding cancer comparative effectiveness research data needs
Abstract
Objectives: Randomized controlled trials remain the gold standard for evaluating cancer intervention efficacy. Randomized trials are not always feasible, practical, or timely and often don't adequately reflect patient heterogeneity and real-world clinical practice. Comparative effectiveness research can leverage secondary data to help fill knowledge gaps randomized trials leave unaddressed; however, comparative effectiveness research also faces shortcomings. The goal of this project was to develop a new model and inform an evolving framework articulating cancer comparative effectiveness research data needs.
Study design and setting: We examined prevalent models and conducted semi-structured discussions with 76 clinicians and comparative effectiveness research researchers affiliated with the Agency for Healthcare Research and Quality's cancer comparative effectiveness research programs.
Results: A new model was iteratively developed and presents cancer comparative effectiveness research and important measures in a patient-centered, longitudinal chronic care model better reflecting contemporary cancer care in the context of the cancer care continuum, rather than a single-episode, acute-care perspective.
Conclusion: Immediately relevant for federally funded comparative effectiveness research programs, the model informs an evolving framework articulating cancer comparative effectiveness research data needs, including evolutionary enhancements to registries and epidemiologic research data systems. We discuss elements of contemporary clinical practice, methodology improvements, and related needs affecting comparative effectiveness research's ability to yield findings clinicians, policy makers, and stakeholders can confidently act on.
Copyright © 2012 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl A):S03-4. J Manag Care Pharm. 2011. PMID: 22074667
-
Building sustainable multi-functional prospective electronic clinical data systems.Med Care. 2012 Jul;50 Suppl:S3-6. doi: 10.1097/MLR.0b013e3182588ed1. Med Care. 2012. PMID: 22692255
-
Epidemiologic and statistical methods for comparative effectiveness research.Heart Fail Clin. 2013 Jan;9(1):29-36. doi: 10.1016/j.hfc.2012.09.007. Epub 2012 Oct 11. Heart Fail Clin. 2013. PMID: 23168315 Free PMC article. Review.
-
The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.Pain Physician. 2011 May-Jun;14(3):E249-82. Pain Physician. 2011. PMID: 21587337 Review.
Cited by
-
Parent, patient and clinician perceptions of outcomes during and following neonatal care: a systematic review of qualitative research.BMJ Paediatr Open. 2018 Oct 9;2(1):e000343. doi: 10.1136/bmjpo-2018-000343. eCollection 2018. BMJ Paediatr Open. 2018. PMID: 30397672 Free PMC article.
-
Integration of Massage Therapy in Outpatient Cancer Care.Int J Ther Massage Bodywork. 2018 Mar 26;11(1):4-10. eCollection 2018 Mar. Int J Ther Massage Bodywork. 2018. PMID: 29593842 Free PMC article.
-
Outcomes of open versus laparoscopic surgery in patients with rectal cancer.Int J Colorectal Dis. 2018 Jan;33(1):99-103. doi: 10.1007/s00384-017-2925-2. Epub 2017 Nov 6. Int J Colorectal Dis. 2018. PMID: 29110087
-
Data-Adaptive Estimation for Double-Robust Methods in Population-Based Cancer Epidemiology: Risk Differences for Lung Cancer Mortality by Emergency Presentation.Am J Epidemiol. 2018 Apr 1;187(4):871-878. doi: 10.1093/aje/kwx317. Am J Epidemiol. 2018. PMID: 29020131 Free PMC article.
-
The COMET Handbook: version 1.0.Trials. 2017 Jun 20;18(Suppl 3):280. doi: 10.1186/s13063-017-1978-4. Trials. 2017. PMID: 28681707 Free PMC article. Review.
References
-
- Sullivan P, Goldmann D. The promise of comparative effectiveness research. JAMA. 2011 Jan 26;305(4):400–401. - PubMed
-
- Smith S. Preface. Medical Care. 2007;45(10 Suppl 2):S1–S2. - PubMed
-
- Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med. 2009 Feb 5;360(6):626–633. - PubMed
-
- Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington DC: National Academies Press; 2009.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
